Boxer Capital’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Boxer Capital’s Portfolio PRVL Stock Details PRVL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,123,105	Closed	-$25.9M	–	91
2020 Q4	$25.9M	Hold	1,123,105	–	–	0.83%	33
2020 Q3	$11.4M	Hold	1,123,105	–	–	0.4%	50
2020 Q2	$16.7M	Hold	1,123,105	–	–	0.74%	37
2020 Q1	$13.7M	Hold	1,123,105	–	–	0.93%	31
2019 Q4	$17.8M	Hold	1,123,105	–	–	1.01%	28
2019 Q3	$13.8M	Hold	1,123,105	–	–	1%	25
2019 Q2	$14.8M	Buy	+1,123,105	New	+$16.4M	1.27%	21

Boxer Capital's PRVL Position: Q1 2021 in Review

Boxer Capital sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 1,123,105 shares — an estimated $25.9M sold.

Boxer Capital first reported a position in PRVL in Q2 2019 and held it in 7 quarters. The position peaked at $25.9M in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

Boxer Capital reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Boxer Capital sold 1,123,105 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $25.9M.
Boxer Capital first reported a position in Prevail Therapeutics Inc. Common Stock in Q2 2019 and held it in 7 quarters.
Boxer Capital's Prevail Therapeutics Inc. Common Stock position peaked at $25.9M in Q4 2020.
0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on Boxer Capital's 13F filing for Q1 2021, filed 17 May 2021.